Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.800
+0.050 (1.05%)
At close: Aug 14, 2026, 4:00 PM EDT
4.752
-0.048 (-1.00%)
After-hours: Aug 14, 2026, 7:35 PM EDT
Relmada Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Relmada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.67. The average 1-year stock price forecast is 163.96% higher than the current stock price, while the lowest is $9.00 (+87.50%) and the highest is $19 (+295.83%).
Price Target: $12.67 (+163.96%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Relmada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates $19 | Buy | Reiterates | $19 | +295.83% | Aug 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +150.00% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +150.00% | Aug 7, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates $14 | Buy | Initiates | $14 | +191.67% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.48
from -1.10
EPS Next Year
-0.56
from -0.48
EPS and Forward PE are based on non-GAAP adjusted numbers.